Amarin Corp Plc (AMRN)

[ggwpq]

I would give the 425,000 UK patients within the R-I label free 6 months (or 3 months or whatever numbers that make sense) Vazkepa supply, which would work down $100 million of inventory (a sunk cost), hoping to retain those patients afterward to generate $765M in annual revenues from UK alone for the next 10 years. It's a more proactive action than just writing off the inventory.